Replimune Group (REPL)
Develops RPx oncolytic immunotherapies for melanoma and other solid tumors.
$13.41
vs last close+0.54 (+4.16%)
Something off on this page? Send us feedback.
Next report
Nov 5, 26
in 44 days
EPS estimate
−$0.78
Revenue estimate
$1.0M
Fiscal quarter
Q2 FY27
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26Jun '26Aug '26Nov '26
Reported−$0.79−$0.82−$0.95−$0.90−$0.77−$0.76−$0.72Pending
Estimate−$0.70−$0.75−$0.83−$0.87−$0.77−$0.73−$0.69−$0.78
Surprise−12.9%−9.3%−14.5%−3.4%−0.2%−4.1%−3.7%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26Jun '26Aug '26Nov '26
Reported—$1.5M—————Pending
Estimate——$500.0K$714.3K$428.6K$3.6M$13.6M$1.0M
Surprise————————
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Mar 2030 | $0.08 | — | — |
| Dec 2029 | $0.05 | — | — |
| Sep 2029 | $0.00 | — | — |
| Jun 2029 | −$0.06 | — | — |
| Mar 2029 | −$0.12 | — | — |
| Dec 2028 | −$0.16 | — | — |
| Sep 2028 | −$0.20 | — | — |
| Jun 2028 | −$0.25 | — | — |
| Mar 2028 | −$0.14 | — | — |
| Dec 2027 | −$0.20 | — | — |
| Sep 2027 | −$0.23 | — | — |
| Jun 2027 | −$0.34 | — | — |
| Mar 2027 | −$0.69 | — | — |
| Dec 2026 | −$0.79 | — | — |
| Nov 2026 | −$0.78 | — | — |
| Aug 2026 | −$0.69 | −$0.72 | −3.7% |
| Jun 2026 | −$0.73 | −$0.76 | −4.1% |
| Feb 2026 | −$0.77 | −$0.77 | −0.2% |
| Nov 2025 | −$0.87 | −$0.90 | −3.4% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| Jun 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| Jun 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| Jul 2018 | |||
| Dec 2017 | |||
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Mar 2030 | $0.08 | — | — | $135.0M | — | — | — |
| Dec 2029 | $0.05 | — | — | $127.7M | — | — | — |
| Sep 2029 | $0.00 | — | — | $117.5M | — | — | — |
| Jun 2029 | −$0.06 | — | — | $106.3M | — | — | — |
| Mar 2029 | −$0.12 | — | — | $95.8M | — | — | — |
| Dec 2028 | −$0.16 | — | — | $88.6M | — | — | — |
| Sep 2028 | −$0.20 | — | — | $79.7M | — | — | — |
| Jun 2028 | −$0.25 | — | — | $70.6M | — | — | — |
| Mar 2028 | −$0.14 | — | — | $64.2M | — | — | — |
| Dec 2027 | −$0.20 | — | — | $56.9M | — | — | — |
| Sep 2027 | −$0.23 | — | — | $50.9M | — | — | — |
| Jun 2027 | −$0.34 | — | — | $42.6M | — | — | — |
| Mar 2027 | −$0.69 | — | — | $27.3M | — | — | — |
| Dec 2026 | −$0.79 | — | — | $8.2M | — | — | — |
| Nov 5, 2026 | −$0.78 | — | — | $1.0M | — | — | — |
| Aug 14, 2026 | −$0.69 | −$0.72 | −3.7% | $13.6M | — | — | −1.5% |
| Jun 29, 2026 | −$0.73 | −$0.76 | −4.1% | $3.6M | — | — | −3.7% |
| Feb 3, 2026 | −$0.77 | −$0.77 | −0.2% | $428.6K | — | — | +5.7% |
| Nov 6, 2025 | −$0.87 | −$0.90 | −3.4% | $714.3K | — | — | −0.9% |
| Aug 7, 2025 | |||||||
| May 22, 2025 | |||||||
| Feb 12, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 16, 2024 | |||||||
| Feb 8, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 18, 2023 | |||||||
| Feb 9, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 19, 2022 | |||||||
| Feb 3, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 6, 2021 | |||||||
| May 20, 2021 | |||||||
| Feb 4, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 7, 2020 | |||||||
| Jun 3, 2020 | |||||||
| Feb 13, 2020 | |||||||
| Nov 11, 2019 | |||||||
| Aug 14, 2019 | |||||||
| Jun 28, 2019 | |||||||
| Feb 14, 2019 | |||||||
| Nov 14, 2018 | |||||||
| Aug 30, 2018 | |||||||
| Jul 23, 2018 | |||||||
| Dec 31, 2017 | |||||||
| Sep 30, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 |